Aquestive Therapeutics, Inc.AQ.STNASDAQ
Loading
Free Cash Flow Growth Under PressureDecelerating
Percentile Rank15
Year-over-Year Change
Year-over-year free cash flow growth rate
Percentile
P15
Within normal range
vs 5Y Ago
-2.4x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | -73.88% |
| Q3 2025 | 94.20% |
| Q2 2025 | -32.68% |
| Q1 2025 | -15.29% |
| Q4 2024 | -21.43% |
| Q3 2024 | 22.22% |
| Q2 2024 | 21.74% |
| Q1 2024 | 16.95% |
| Q4 2023 | -37.01% |
| Q3 2023 | 155.45% |
| Q2 2023 | -30.82% |
| Q1 2023 | 140.91% |
| Q4 2022 | 174.16% |
| Q3 2022 | -270.83% |
| Q2 2022 | 25.00% |
| Q1 2022 | 81.40% |
| Q4 2021 | -605.88% |
| Q3 2021 | -37.04% |
| Q2 2021 | -58.78% |
| Q1 2021 | -12.90% |
| Q4 2020 | 30.57% |
| Q3 2020 | -11.22% |
| Q2 2020 | 42.36% |
| Q1 2020 | 25.40% |
| Q4 2019 | -25.05% |
| Q3 2019 | 4461.34% |
| Q2 2019 | -98.29% |
| Q1 2019 | 141435.23% |
| Q4 2018 | 100.56% |
| Q3 2018 | -254.49% |
| Q2 2018 | -41.29% |
| Q1 2018 | 158.10% |
| Q4 2017 | -193.94% |
| Q3 2017 | -29.37% |
| Q2 2017 | 859.22% |
| Q1 2017 | -126.80% |
| Q4 2016 | -46.67% |
| Q3 2016 | 35.64% |
| Q2 2016 | -57.21% |
| Q1 2016 | 5058.55% |